7746-27-2

Usage

Uses

Used in Pharmaceutical Research:
6-Bromo-3-methyl indazole is used as a key intermediate in the synthesis of novel drugs and chemical compounds. Its unique structure and potential pharmacological properties contribute to the development of new therapeutic agents with improved efficacy and selectivity.
Used in Chemical Research:
In the field of chemical research, 6-Bromo-3-methyl indazole serves as a valuable building block for the creation of various chemical compounds. Its reactivity and functional groups enable the synthesis of diverse molecules with potential applications in various industries.
Used in Drug Development:
6-Bromo-3-methyl indazole is utilized as a starting material in the design and development of new drugs. Its unique chemical properties allow for the exploration of novel therapeutic targets and the optimization of drug candidates for improved pharmacokinetics, safety, and efficacy.
Used in Medicinal Chemistry:
6-Bromo-3-methyl indazole plays a crucial role in medicinal chemistry, where it is employed as a structural motif for the modification and optimization of drug candidates. Its presence in a molecule can influence the binding affinity, selectivity, and overall pharmacological profile of a compound.
Used in Biochemical Studies:
6-Bromo-3-methyl indazole is also used in biochemical studies to investigate the interactions between small molecules and biological targets. Its unique structure allows researchers to probe the binding mechanisms and explore the potential of 6-Bromo-3-methyl indazole as a modulator of biological processes.

Upstream product

• 947685-09-8 1-(4-bromo-2-fluorophenyl)ethanone hydrazone 
• 625446-22-2 4-bromo-2-fluoroacetophenone 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 353282-88-9 1-(4-bromo-2-fluorophenyl)ethanol 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 
• 801303-33-3 4-bromo-2-fluoro-N-methoxy-N-methylbenzamide 

Downstream Products

• 1227911-51-4 3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-1-indazole 
• 1095539-84-6 6-bromo-1,3-dimethyl-1H-indazole 
• 1142189-49-8 6-bromo-2,3-dimethyl-1H-indazole 
• 1300584-82-0 2-((4-amino-3-(3-methyl-1H-indazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-phenyl-4H-chromen-4-one 
• 1300584-95-5 2-((4-amino-3-(3-methyl-1H-indazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(3-fluorophenyl)-4H-chromen-4-one 
• 1300585-01-6 2-((4-amino-3-(3-methyl-1H-indazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-6-fluoro-3-phenyl-4H-chromen-4-one 
• 1300585-02-7 2-(1-(4-amino-3-(3-methyl-1H-indazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-3-phenyl-4H-chromen-4-one 
• 1300585-03-8 2-(1-(4-amino-3-(3-methyl-1H-indazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-phenyl-4H-chromen-4-one 
• 1300585-12-9 2-(1-(4-amino-3-(3-methyl-1H-indazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 
• 1300585-36-7 2-(1-(4-amino-3-(3-methyl-1H-indazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one 
• 1300586-44-0 2-(1-(4-amino-3-(1,3-dimethyl-1H-indazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-3-(3-fluorophenyl)-4H-chromen-4-one 
• 1300586-47-3 2-(1-(4-amino-3-(2,3-dimethyl-2H-indazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-3-(3-fluorophenyl)-4H-chromen-4-one 
• 1300582-62-0 2,3-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole 
• 1394120-03-6 4-[1-(2-aminopyrimidin-4-yl)-3-methylindazol-6-yl]-2-[1-(triphenylmethyl)imidazol-4-yl]but-3-yn-2-ol 

Relevant academic research and scientific papers

HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions in need of inhibition of heparan sulfate biosynthesis.

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS

JAK1 inhibitors of structural formula (I), wherein Ar1, Ar2, Q, W, X, Y, and Z are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

NOVEL KINASE MODULATORS

The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

CHEMICAL COMPOUNDS

The invention is directed to 6-(4-pyι?midinyl)-1 H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1 - R4 are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Therapeutic Piperazines

The invention includes a compound of formula I: wherein R1, X, Z, n, and m have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administra